SCHEMBL8015186

SCHEMBL8015186

CCc1cc2c(OC)cccc2n1C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 1/20 0.47
MTNR1B P49286 11/20 0.45
MTNR1A P48039 8/20 0.45
DHFR P00374 1/20 0.40
HTR2C P28335 1/20 0.40
CYP19A1 P11511 1/20 0.40
NQO2 P16083 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TNFRSF1A P19438 1/20 0.38
ASH1L Q9NR48 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2276436 0.81 MTNR1B (0.44) RHEBMTNR1BMTNR1AHTR2C
SCHEMBL23282978 0.80 MTNR1B (0.46) MTNR1BMTNR1AHTR2CKDM4EALDH1A1
SCHEMBL434299 0.77 CYP19A1 (0.46) HTR2CCYP19A1NQO2KDM4EALDH1A1
SCHEMBL26473 0.76 MTNR1B (0.67) MTNR1BMTNR1ACYP19A1MAPTKMT2A
SCHEMBL8025948 0.76 DRD2 (0.42) RHEBMTNR1B
SCHEMBL8015473 0.76 MAPT (0.42) RHEBDHFRHTR2CKDM4EALDH1A1
SCHEMBL17680608 0.76 RHEB (0.43) RHEBDHFRKDM4EALDH1A1MEN1
SCHEMBL25171221 0.76 DHFR (0.42) RHEBDHFRNQO2KDM4EALDH1A1
SCHEMBL19644367 0.74 NR4A2 (0.46) KDM4EALDH1A1MEN1MAPTHPGD
SCHEMBL24451609 0.73 HTR2C (0.43) MTNR1BMTNR1AHTR2CCYP19A1NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384090-B2 Spiropyrrolidine derived antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2022-07-12 US disclosed
US-20220162216-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2022-05-26 US disclosed
WO-2000061554-A1 1-AMINO ETHYLINDOLE DERIVATIVES FOR THE TREATMENT OF URINARY INCONTINENCE SANOFI-SYNTHELABO (FR) 2000-10-19 WO disclosed
WO-2000061553-A1 2-AMINOETHYL-INDOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE SANOFI-SYNTHELABO (FR) 2000-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384090-B2 Spiropyrrolidine derived antiviral agents ACE, ACE2, REN RHEB 836/4885MTNR1B 3417/4885MTNR1A 3792/4885
US-20220162216-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ACE, ACE2, REN RHEB 536/4885MTNR1B 3569/4885MTNR1A 3825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.